suPARnostic® provides improved risk stratification of patients in the emergency department.
Eliminate doubt in clinical decisions
Using suPAR in clinical care allows healthcare professionals to identify and discharge more patients, reducing stress, crowding, and healthcare costs. Earlier Identification of high-risk patients can provide faster clinical intervention and better patient outcomes.
suPARnostic® is the only CE-IVD certified product range applied for clinical measurement of suPAR in human plasma and serum. It enables healthcare professionals to make fast clinical decisions based on prognostic evidence across diseases.
A low suPAR level (under 4 ng/ml) indicates a good prognosis and supports the decision to discharge the patient.
A high suPAR level (over 6 ng/ml) indicates the presence, progression, and severity of disease, organ damage, mortality risk and supports further clinical attention.
How to interpret suPAR results
suPAR level < 4 ng/mL
Supports patient discharge
suPAR level > 6 ng/mL
Supports patient hospitalisation
Achieve significant healthcare cost savings
In emergency departments and hospital wards, suPARnostic® can identify low-risk patients, resulting in earlier and safer discharges. A study examining the effectiveness of using suPAR as a risk stratification tool showed that hospitals could save one bed for 24 hours in every four patients admitted.*
*Schultz et al. Disease Markers, 2019, 10;1-8A sub study of the interventional TRIAGE III trial, comparing patients with a valid suPAR measurement at admission to those without in EDs at two university hospitals in the Capital Region of Denmark.
“The key challenge for the emergency department is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”
MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen
Early anakinra treatment of COVID-19 patients guided by suPAR saves lives
Get our whitepaper about the study results and read more about how an early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.